Kidney damage in some rheumatic diseases

Authors

  • O.I. Taran Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine

DOI:

https://doi.org/10.22141/2307-1257.6.2.2017.102792

Keywords:

rheumatoid arthritis, ankylosing spondylarthritis, psoriatic arthritis, AA-amyloidosis, interstitial nephritis, cytotoxic agents, biological agents, non-steroidal anti-inflammatory drugs

Abstract

Rheumatic disease with visceral manifestations pose a potential problem for the disease course and its prognosis. Such visceral manifestations may include kidney damage or complications, particularly in certain cases bone, joint and muscular manifestations of rheumatic disease. Glomerular immune inflammatory diseases appear in cases where the rheumatic disease progresses to the point of becoming a systemic inflammatory process; AA-amyloidosis appears in cases of prolonged active articular process; while tubulo-interstitial lesion occurs during the treatment with non-steroidal anti-inflammatory drugs and analgesics. Progressive nature of kidney failure in rheumatic diseases, leading to the development of terminal renal insufficiency, presents a problem for the affected individuals in terms of their ability to live in conditions of renal replacement therapy.

Downloads

Download data is not yet available.

References

Kovalenkо VM, Shuba NM, editors. Nacіonal'nij pіdruchnik z revmatologії [The national textbook of Rheumatology]. Kyiv: MORION; 2013. pp. 381-436. (In Ukrainian).

KDIGO guidelines on glomerulonephritis. Pochki. 2012;1:19-30. ( In Ukrainian).

Kozlovskaya L, RameevV. Modern approaches to treatment of amyloidosis. Sovremennaja medicinskaja nauka. 2012,1:4-15.(In Russian).

Batushin MM, Terentev VP, Mitrieva OV, Povilaytite PE. Hronicheskaja bolezn' pochek [Chronic kidney disease]. Elista, ZAOrNPP “Dzangar”; 2009. 126 p. (In Russian).

Muraviov UV. Genetically engineered biological preparations in the treatment of AA Amyloidosis in reumatoid patients. Nauchno-prakticheskaja revmatologija. 2010;2:66-70. (In Russian).

Soliman MM, Hyrich KL, Lunt M, Watson KD, Symmons DD, Ashcroft DM; The British Society of Rheumatology biologics Register (BSRBR). Effectiveness of Rituximab in Patients with Rheumatoid Arthritis: Observational Study from the BSRBR. J Rheumatol. 2012 Feb; 39(2):240-6. PMID: 22174201. doi: 10.3899/jrheum.110610.

Kozlovskaya L, Rameev V, Sarkisov I. Treatment of Amyloidosis. Vrach;2007:6:38-41.(In Russian).

Shulutko EI. Nefrologija 2000. Sovremennoe sostojanie problemy [Nephrology 2002. Current state]. St. Petersburg: Renkor; 2002. 780 p.(In Russian).

Tareeva IE, editor. Nefrologija. Rukovodstvo dlja vrachej [Nephrology. Guide for physicians]. Moscow: Medicine; 2009. 688 p. (In Russian).

Kolesnik NA, editor. Porazhenie pochek, obuslovlennye revmaticheskimi zabolevanijami [Damage to the kidneys caused by rheumatic diseases]. Kyiv; 2004. (In Russian).

Segasothy M, Samad SA, Zulfigar A, Bennett WM. Chronic renal disease and papillary necrosis associated with the ling-term use of nonsteroidal anti-inflammatory drugs as the sole or predominant analgesic. Am J .Kidney Dis. 1994 .Jul;24(1):17-24. PMID: 8023820.

Calvo-Alén J, De Cos MA, Rodriguez-Valverde V, et al. Subclinical renal toxicity in rheumatic patients receiving long-term treatment with nonsteroidal anti-inflammatory drugs. J Rheumatol. 1994;21(9):1742-7.

Jonson RW. Ankylosing spondilitis. In: West SJ. Secret of Nephrology: Translated from English .St. Petersburg: Publishing house BINOM — Nevsky Dialect; 1999. 305 p. (In Russian).

Downloads

Published

2021-09-09

How to Cite

Taran, O. (2021). Kidney damage in some rheumatic diseases. KIDNEYS, 6(2), 121–127. https://doi.org/10.22141/2307-1257.6.2.2017.102792

Issue

Vol. 6 No. 2 (2017)

Section

Lecture

License

Copyright (c) 2017 O.I. Taran

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.